Without
comprehensive
biomarker testing,
how do you know
which treatments are
most likely to be effective?
Which Five Cancers
Most Commonly
Overexpress HER2?
Thinking about breast cancer isn't enough.
GET THE ANSWER HER2In Which Cancers
Is MGMT Expression
Level Important?
Thinking only brain cancer? Think again.
GET THE ANSWER MGMTWhat’s The Connection
Between SPARC and
Cancer Treatment?
Thinking about albumin might SPARC an idea.
GET THE ANSWER SPARCCancer Biomarkers
Clues About a Patient's Unique Cancer
Cancer biomarkers, which include genes, proteins and
other molecules are important because they impact
biological processes by which cancer cells proliferate.
Identifying clinically relevant and patient-specific
biomarkers can help guide more effective and targeted treatment.
Targeting Cancer
On average, only approximately 25% of patients respond to prescribed cancer therapies.
But biomarkers and molecular profiling are helping to improve the likelihood of response by targeting therapies.
Biomarkers provide clues about each patient's cancer and which treatments are more likely to fight it effectively. Armed with more information about their patient's molecularly distinct disease, doctors can recommend personalized treatment designed for maximum effectiveness.
Sophisticated, comprehensive molecular profiling identifies those biomarkers that are important for each cancer through a variety of tests including, immunohistochemistry (IHC), fluorescent in situ hybridization (FISH), microarray analysis and DNA sequencing.
In a pilot study, treatment recommended by molecular profiling has been shown to increase progression-free survival among some patients.*
See Sandy's Biomarker Story* http://jco.ascopubs.org/content/early/2010/10/01/JCO.2009.26.5983.abstract
Sandy's Biomarkers Story
PATIENT: Sandy Fehrman
FIRST DIAGNOSED:
1992, breast cancer
(metastatic carcinoma)
RECURRENCE:
2003, metastatic disease
to lung, liver, bone
BIOMARKERS IDENTIFIED:
HER2, PDGFR, TOP2B, MGMT
TARGETED TREATMENTS:
trastuzumab to target HER2,
sunitinib to target PDGFR
… Caris Target Now™ has meant my life.” — Sandy
Caris Target Now™
New biomarker discoveries are being made; however, it is already possible to apply the latest research to real-world cancer treatment. Many studies confirm that important biomarker targets are expressed in multiple cancer types.
Caris Target Now combines comprehensive molecular pathology and tumor profiling with an exhaustive evidence-based review of the latest clinical literature on biomarkers and their correlation to potential drug response in order to provide treating physicians with the information needed to personalize cancer therapy for their patients.
Each report contains the expression levels of relevant biomarkers, the drugs associated with response and those that are unlikely to be effective for that tumor.
Contact a RepresentativeDownload a sample
Caris Target Now Report
We Can Help